HRT and Body Composition: How Hormone Replacement Therapy Affects Fat, Muscle, and Bone on a DEXA Scan

Hormone replacement therapy (HRT) is one of the most effective treatments for managing menopause symptoms. But beyond relieving hot flushes and improving sleep, HRT has measurable effects on your body composition, changing how fat is stored, how quickly muscle is lost, and whether bone density stabilises or continues to decline.

A body composition DEXA scan is the most precise way to track these changes. Unlike scales or BMI, a DEXA scan separates your body into three distinct compartments: fat mass, lean mass (muscle), and bone mineral density. This makes it possible to see exactly what HRT is doing beneath the surface.

Quick Answer: HRT can reduce visceral (abdominal) fat accumulation, slow age-related muscle loss, and improve bone mineral density. A DEXA scan before and after starting HRT gives you an objective baseline and a way to measure progress over time.

The decline in oestrogen that occurs during menopause triggers three significant shifts in body composition. Understanding these changes is the first step toward managing them effectively.

Fat redistribution to the abdomen. Before menopause, oestrogen directs fat storage toward the hips, thighs, and buttocks (a pattern called gynoid distribution). As oestrogen drops, fat increasingly accumulates around the abdomen and internal organs. This visceral fat is metabolically active and raises the risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome. Research published in the International Journal of Obesity found that the menopausal transition is associated with a significant increase in visceral adipose tissue, independent of ageing alone.

Accelerated muscle loss. Women lose approximately 0.6% of their lean body mass per year after menopause, according to data from longitudinal cohort studies. This rate is faster than pre-menopausal age-related muscle decline and contributes to reduced strength, lower resting metabolic rate, and increased fall risk.

Rapid bone density decline. The first five to seven years after menopause see the fastest rate of bone loss, with some women losing up to 20% of their bone density during this window. The NHS estimates that osteoporosis affects around 3 million people in the UK, with postmenopausal women at the highest risk. A bone density DEXA scan is the clinical standard for detecting this loss early.

One of the most measurable effects of HRT is its influence on where your body stores fat. Oestrogen replacement helps reverse the shift toward central fat accumulation that menopause causes.

Oestrogen inhibits lipoprotein lipase in visceral adipose tissue, which reduces fat deposition around the internal organs. At the same time, it activates hormone-sensitive lipase, the enzyme responsible for breaking down stored triglycerides. The combined effect is a reduction in abdominal fat and a return toward the pre-menopausal pattern of fat storage in the hips and thighs.

A study published in The Journal of Clinical Endocrinology and Metabolism (the OsteoLaus cohort) found that menopausal hormone therapy was associated with reduced total and visceral adiposity when measured by DEXA. Women on HRT had lower trunk fat and improved waist-to-hip ratios compared with untreated women of the same age and BMI.

Clinical data also suggests that HRT attenuates postmenopausal weight gain by approximately 40%, not because it causes weight loss directly, but because it prevents the metabolic slowdown and fat redistribution that would otherwise occur. A randomised, double-blind, placebo-controlled trial published in the American Journal of Obstetrics and Gynecology confirmed that HRT improved body fat distribution and insulin sensitivity in menopausal women, even when total body weight remained stable.

On a DEXA scan, these changes appear as a reduction in android (abdominal) fat and an improvement in the android-to-gynoid fat ratio, which is one of the strongest body composition predictors of cardiovascular risk.

Oestrogen plays a direct role in muscle protein synthesis and repair. When oestrogen levels fall during menopause, the rate of muscle breakdown increases while the capacity for muscle regeneration declines. HRT can partially counteract this process.

A 2025 study published in Skeletal Radiology, using repeated DEXA measures from the Baltimore Longitudinal Study of Aging, found that women who used HRT showed slower rates of lean mass decline compared with non-users. The protective effect was most pronounced in the appendicular skeleton (arms and legs), which is the muscle mass most relevant to functional strength and mobility.

A meta-analysis of 12 randomised trials reported in JAMA Network Open found a consistent trend toward lean body mass preservation in women on oestrogen-based therapy, although the authors noted that the magnitude of benefit was modest and varied depending on the type and duration of HRT.

The clinical implication is straightforward: HRT alone will not build muscle, but it can slow the rate at which you lose it. When combined with resistance training and adequate protein intake, HRT creates a more favourable hormonal environment for maintaining lean mass through the menopausal transition and beyond.

A DEXA scan quantifies lean mass by region, so you can see whether your arms, legs, and trunk are maintaining muscle over time or whether specific areas are declining faster than others.

Bone protection is one of the best-established benefits of HRT. Oestrogen is essential for maintaining the balance between bone formation (by osteoblasts) and bone resorption (by osteoclasts). When oestrogen drops after menopause, resorption outpaces formation, and bone density falls.

The Women’s Health Initiative, one of the largest randomised controlled trials of HRT ever conducted, demonstrated that combined oestrogen-progestogen therapy reduced hip fractures by 34% and vertebral fractures by 34%. These findings have been replicated across multiple studies and are reflected in current NICE guidance, which recommends HRT as a first-line option for preventing osteoporosis in women with premature ovarian insufficiency and as a treatment consideration for postmenopausal women at risk of fragility fractures.

For women with premature ovarian insufficiency (menopause before age 40), NHS guidance recommends a baseline bone density scan and effective oestrogen replacement continued until at least the age of 51 to prevent early-onset osteoporosis.

The degree of bone density improvement depends on the dose, route of administration, and how long HRT is continued. Transdermal oestradiol at standard doses typically stabilises bone density within the first year and can produce measurable increases of 2 to 5% over two to three years at the lumbar spine and hip, according to a review published in Annals of Internal Medicine.

To learn more about how a DEXA scan measures bone density and what your T-scores mean, see our guide to how DEXA scanning works.

Bathroom scales tell you your total weight. BMI tells you whether that weight is proportionate to your height. Neither of these measurements can distinguish between fat, muscle, and bone, and neither can show you where fat is stored or whether you are losing bone.

A DEXA scan provides a three-compartment analysis that separates fat mass, lean mass, and bone mineral density across your entire body and by region. This level of detail is essential for understanding the effects of HRT because the therapy changes all three compartments simultaneously, often in subtle ways that total weight alone would miss entirely.

For example, a woman on HRT might see her weight remain stable over 12 months while her DEXA results show a 1.5 kg reduction in trunk fat, a 0.8 kg increase in lean mass, and a 3% improvement in lumbar spine bone density. Without a DEXA scan, she would have no way of knowing these changes had occurred.

DEXA also measures visceral adipose tissue (VAT) directly, which is the fat compartment most closely linked to metabolic and cardiovascular risk. Tracking your VAT level before and after starting HRT gives you and your clinician a clear, objective metric for assessing whether the therapy is having the intended protective effect on metabolic health.

The timing of your DEXA scan matters. Here is a practical framework for using DEXA alongside HRT.

Before starting HRT (baseline scan). A DEXA scan taken before you begin therapy establishes your starting point for fat distribution, lean mass, and bone density. This baseline makes every future scan more meaningful because changes can be measured against a known reference.

12 to 18 months after starting HRT. Most body composition changes from HRT become measurable within this timeframe. A follow-up scan at this point can confirm whether fat redistribution is occurring, whether lean mass is being preserved, and whether bone density has stabilised or improved.

Ongoing monitoring every one to two years. For women on long-term HRT, periodic DEXA scans help ensure the therapy continues to deliver its protective effects. This is particularly important for bone density, where a change in HRT dose or formulation can affect the rate of bone maintenance.

If you stop HRT. Bone density can decline rapidly after discontinuing oestrogen therapy. A DEXA scan six to twelve months after stopping HRT helps identify whether bone loss is accelerating and whether additional interventions are needed.

Does HRT cause weight gain?

No. The evidence shows that HRT actually attenuates the weight gain associated with menopause. Clinical trials have found that women on HRT gain approximately 40% less weight than untreated women over the same period. What HRT does change is where fat is stored, shifting it away from the abdomen and toward a healthier distribution pattern.

Can a DEXA scan show whether HRT is working?

Yes. A DEXA scan measures fat mass, lean mass, and bone density with high precision. By comparing a baseline scan (taken before or shortly after starting HRT) with a follow-up scan 12 to 18 months later, you can see objective changes in all three compartments. This is particularly useful for bone density, where improvements may not produce any noticeable symptoms.

How long does it take for HRT to affect body composition?

Fat redistribution changes typically become noticeable within three to six months. Bone density improvements are usually measurable after 12 to 24 months of continuous therapy. Muscle preservation effects are more gradual and depend heavily on whether resistance exercise is also part of your routine.

Is HRT safe for bone health long-term?

Current NICE guidelines support the use of HRT for osteoporosis prevention in postmenopausal women, particularly those with premature ovarian insufficiency. The Women’s Health Initiative demonstrated significant fracture risk reduction with HRT. Your GP or specialist can advise on the appropriate duration based on your individual risk profile.

Should I get a DEXA scan even if I am not on HRT?

Yes. Any woman going through perimenopause or menopause can benefit from a baseline DEXA scan, regardless of whether she is taking HRT. The scan identifies your current bone density, fat distribution, and lean mass, all of which are important health markers during this transition. If your results show accelerated bone loss or unfavourable fat distribution, this information can help guide treatment decisions.

If you are considering HRT, currently taking HRT, or have recently stopped, a DEXA scan gives you the clinical data you need to understand what is happening inside your body. Our Harley Street clinic offers both body composition and bone density DEXA scans, with results reviewed by Dr Emil Gadimali.

Call us on 0207 637 8227 or book your body composition DEXA scan online to get started. Your scan takes approximately 15 minutes and provides a detailed breakdown of your fat, muscle, and bone health.

Written by Dr Emil Gadimali

Hormone replacement therapy (HRT) is one of the most effective treatments for managing menopause symptoms. But beyond relieving hot flushes and improving sleep, HRT has measurable effects on your body composition, changing how fat is stored, how quickly muscle is lost, and whether bone density stabilises or continues to decline.

A body composition DEXA scan is the most precise way to track these changes. Unlike scales or BMI, a DEXA scan separates your body into three distinct compartments: fat mass, lean mass (muscle), and bone mineral density. This makes it possible to see exactly what HRT is doing beneath the surface.

Quick Answer: HRT can reduce visceral (abdominal) fat accumulation, slow age-related muscle loss, and improve bone mineral density. A DEXA scan before and after starting HRT gives you an objective baseline and a way to measure progress over time.

The decline in oestrogen that occurs during menopause triggers three significant shifts in body composition. Understanding these changes is the first step toward managing them effectively. We explored these hormonal shifts in detail in our guide to perimenopause and body composition, which covers the earlier stages of this transition.

Fat redistribution to the abdomen. Before menopause, oestrogen directs fat storage toward the hips, thighs, and buttocks (a pattern called gynoid distribution). As oestrogen drops, fat increasingly accumulates around the abdomen and internal organs. This visceral fat is metabolically active and raises the risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome. Research published in the International Journal of Obesity found that the menopausal transition is associated with a significant increase in visceral adipose tissue, independent of ageing alone.

Accelerated muscle loss. Women lose approximately 0.6% of their lean body mass per year after menopause, according to data from longitudinal cohort studies. This rate is faster than pre-menopausal age-related muscle decline and contributes to reduced strength, lower resting metabolic rate, and increased fall risk.

Rapid bone density decline. The first five to seven years after menopause see the fastest rate of bone loss, with some women losing up to 20% of their bone density during this window. The NHS estimates that osteoporosis affects around 3 million people in the UK, with postmenopausal women at the highest risk. A bone density DEXA scan is the clinical standard for detecting this loss early.

One of the most measurable effects of HRT is its influence on where your body stores fat. Oestrogen replacement helps reverse the shift toward central fat accumulation that menopause causes.

Oestrogen inhibits lipoprotein lipase in visceral adipose tissue, which reduces fat deposition around the internal organs. At the same time, it activates hormone-sensitive lipase, the enzyme responsible for breaking down stored triglycerides. The combined effect is a reduction in abdominal fat and a return toward the pre-menopausal pattern of fat storage in the hips and thighs.

A study published in The Journal of Clinical Endocrinology and Metabolism (the OsteoLaus cohort) found that menopausal hormone therapy was associated with reduced total and visceral adiposity when measured by DEXA. Women on HRT had lower trunk fat and improved waist-to-hip ratios compared with untreated women of the same age and BMI.

Clinical data also suggests that HRT attenuates postmenopausal weight gain by approximately 40%, not because it causes weight loss directly, but because it prevents the metabolic slowdown and fat redistribution that would otherwise occur. A randomised, double-blind, placebo-controlled trial published in the American Journal of Obstetrics and Gynecology confirmed that HRT improved body fat distribution and insulin sensitivity in menopausal women, even when total body weight remained stable.

On a DEXA scan, these changes appear as a reduction in android (abdominal) fat and an improvement in the android-to-gynoid fat ratio, which is one of the strongest body composition predictors of cardiovascular risk.

Oestrogen plays a direct role in muscle protein synthesis and repair. When oestrogen levels fall during menopause, the rate of muscle breakdown increases while the capacity for muscle regeneration declines. HRT can partially counteract this process.

A 2025 study published in Skeletal Radiology, using repeated DEXA measures from the Baltimore Longitudinal Study of Aging, found that women who used HRT showed slower rates of lean mass decline compared with non-users. The protective effect was most pronounced in the appendicular skeleton (arms and legs), which is the muscle mass most relevant to functional strength and mobility.

A meta-analysis of 12 randomised trials reported in JAMA Network Open found a consistent trend toward lean body mass preservation in women on oestrogen-based therapy, although the authors noted that the magnitude of benefit was modest and varied depending on the type and duration of HRT.

The clinical implication is straightforward: HRT alone will not build muscle, but it can slow the rate at which you lose it. When combined with resistance training and adequate protein intake, HRT creates a more favourable hormonal environment for maintaining lean mass through the menopausal transition and beyond.

A DEXA scan quantifies lean mass by region, so you can see whether your arms, legs, and trunk are maintaining muscle over time or whether specific areas are declining faster than others.

Bone protection is one of the best-established benefits of HRT. Oestrogen is essential for maintaining the balance between bone formation (by osteoblasts) and bone resorption (by osteoclasts). When oestrogen drops after menopause, resorption outpaces formation, and bone density falls.

The Women’s Health Initiative, one of the largest randomised controlled trials of HRT ever conducted, demonstrated that combined oestrogen-progestogen therapy reduced hip fractures by 34% and vertebral fractures by 34%. These findings have been replicated across multiple studies and are reflected in current NICE guidance, which recommends HRT as a first-line option for preventing osteoporosis in women with premature ovarian insufficiency and as a treatment consideration for postmenopausal women at risk of fragility fractures.

For women with premature ovarian insufficiency (menopause before age 40), NHS guidance recommends a baseline bone density scan and effective oestrogen replacement continued until at least the age of 51 to prevent early-onset osteoporosis.

The degree of bone density improvement depends on the dose, route of administration, and how long HRT is continued. Transdermal oestradiol at standard doses typically stabilises bone density within the first year and can produce measurable increases of 2 to 5% over two to three years at the lumbar spine and hip, according to a review published in Annals of Internal Medicine.

To learn more about how a DEXA scan measures bone density and what your T-scores mean, see our guide to how DEXA scanning works.

Bathroom scales tell you your total weight. BMI tells you whether that weight is proportionate to your height. Neither of these measurements can distinguish between fat, muscle, and bone, and neither can show you where fat is stored or whether you are losing bone.

A DEXA scan provides a three-compartment analysis that separates fat mass, lean mass, and bone mineral density across your entire body and by region. This level of detail is essential for understanding the effects of HRT because the therapy changes all three compartments simultaneously, often in subtle ways that total weight alone would miss entirely.

For example, a woman on HRT might see her weight remain stable over 12 months while her DEXA results show a 1.5 kg reduction in trunk fat, a 0.8 kg increase in lean mass, and a 3% improvement in lumbar spine bone density. Without a DEXA scan, she would have no way of knowing these changes had occurred.

DEXA also measures visceral adipose tissue (VAT) directly, which is the fat compartment most closely linked to metabolic and cardiovascular risk. Tracking your VAT level before and after starting HRT gives you and your clinician a clear, objective metric for assessing whether the therapy is having the intended protective effect on metabolic health.

The timing of your DEXA scan matters. Here is a practical framework for using DEXA alongside HRT.

Before starting HRT (baseline scan). A DEXA scan taken before you begin therapy establishes your starting point for fat distribution, lean mass, and bone density. This baseline makes every future scan more meaningful because changes can be measured against a known reference.

12 to 18 months after starting HRT. Most body composition changes from HRT become measurable within this timeframe. A follow-up scan at this point can confirm whether fat redistribution is occurring, whether lean mass is being preserved, and whether bone density has stabilised or improved.

Ongoing monitoring every one to two years. For women on long-term HRT, periodic DEXA scans help ensure the therapy continues to deliver its protective effects. This is particularly important for bone density, where a change in HRT dose or formulation can affect the rate of bone maintenance.

If you stop HRT. Bone density can decline rapidly after discontinuing oestrogen therapy. A DEXA scan six to twelve months after stopping HRT helps identify whether bone loss is accelerating and whether additional interventions are needed.

Does HRT cause weight gain?

No. The evidence shows that HRT actually attenuates the weight gain associated with menopause. Clinical trials have found that women on HRT gain approximately 40% less weight than untreated women over the same period. What HRT does change is where fat is stored, shifting it away from the abdomen and toward a healthier distribution pattern.

Can a DEXA scan show whether HRT is working?

Yes. A DEXA scan measures fat mass, lean mass, and bone density with high precision. By comparing a baseline scan (taken before or shortly after starting HRT) with a follow-up scan 12 to 18 months later, you can see objective changes in all three compartments. This is particularly useful for bone density, where improvements may not produce any noticeable symptoms.

How long does it take for HRT to affect body composition?

Fat redistribution changes typically become noticeable within three to six months. Bone density improvements are usually measurable after 12 to 24 months of continuous therapy. Muscle preservation effects are more gradual and depend heavily on whether resistance exercise is also part of your routine.

Is HRT safe for bone health long-term?

Current NICE guidelines support the use of HRT for osteoporosis prevention in postmenopausal women, particularly those with premature ovarian insufficiency. The Women’s Health Initiative demonstrated significant fracture risk reduction with HRT. Your GP or specialist can advise on the appropriate duration based on your individual risk profile.

Should I get a DEXA scan even if I am not on HRT?

Yes. Any woman going through perimenopause or menopause can benefit from a baseline DEXA scan, regardless of whether she is taking HRT. The scan identifies your current bone density, fat distribution, and lean mass, all of which are important health markers during this transition. If your results show accelerated bone loss or unfavourable fat distribution, this information can help guide treatment decisions.

If you are considering HRT, currently taking HRT, or have recently stopped, a DEXA scan gives you the clinical data you need to understand what is happening inside your body. Our Harley Street clinic offers both body composition and bone density DEXA scans, with results reviewed by Dr Emil Gadimali.

Call us on 0207 637 8227 or book your body composition DEXA scan online to get started. Your scan takes approximately 15 minutes and provides a detailed breakdown of your fat, muscle, and bone health.

Written by Dr Emil Gadimali